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 CONTINUOUS SUBCUTANEOUS INFUSION VERSUS MULTIPLE DOSE 
INJECTION OF INSULIN FOR NEWLY-DIAGNOSED T1D PAEDIATRIC 
PATIENTS: A COST-UTILITY ANALYSIS 
Ridyard CH1, Blair J2, Hughes DA1, on behalf of the SCIPI Trial Investigators .3 
1Bangor University, Bangor, United Kingdom, 2Alder Hey Children's NHS Foundation Trust, Liverpool, United 
Kingdom, 3Clinical Trials Research Centre, Liverpool, United Kingdom 
OBJECTIVES: Continuous subcutaneous insulin infusions (CSII) and multiple daily injections (MDI) with insulin 
are alternative methods of glycaemic control in type 1 diabetes (T1D) aimed to reduce the risk of developing long 
term microvascular and macrovascular complications. The SCIPI trial (ISRCTN29255275) compared the clinical 
and cost-effectiveness of CSII treatment with MDI in paediatric patients from the perspective of the 
NHS. METHODS: Children (aged 7months-15years) with newly-diagnosed T1D were randomised equally to CSII 
or MDI for treatment and stratified by age and treatment centre. Resource use (prescribed insulin, concomitant 
medications, devices, consumables, inpatient, outpatient, emergency, adverse events, general practitioner and 
school visits) was collected at randomisation, 3, 6, 9 and 12 month intervals. Quality adjusted life years (QALYs) 
were assessed by the Health Utilities Index (Mark II) completed at all study visits. RESULTS: 293 children were 
randomised to the trial (median age 9.8 years; median HbA1c 11.8%). Over 12 months, mean total costs were 
higher by £1,863 (95% CI, £1,620, £2,137) for CSII than for MDI (£4,404 vs £2,541); with the majority of this 
difference (£1,177) due to the additional cost of consumables and devices (annualised cost of £600 CSII versus 
£80 MDI). There were no significant differences in QALYs between CSII (0.910) and MDI (0.916) [difference in 
means of -0.006 QALYs (95% CI, -0.031, 0.018)] and none of the sensitivity analyses affected the base case 
result of CSII being dominated by MDI. CONCLUSIONS: CSII is not cost effective in patients representative of 
the study population and is dominated by MDI. However, the generalisability of our data beyond 12 months is 
uncertain. 
 
